Apellis Pharmaceuticals Inc (NASDAQ:APLS) currently has a daily average trading volume of 2.52M but it saw 1690641 shares traded in last market. With a market cap of 2.23B USD, the company’s current market price of $17.78 came rising about 2.07 while comparing to the previous closing price of $17.42. In past 52 weeks, the stock remained buoying in the range of price level as high as $43.99 and as low as $16.10.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Raymond James which downgraded the stock as “Outperform” in its note to investors issued on May 09, 2025, recommending a price target of $52 for it. BofA Securities downgraded its recommendation for the stock as a “Neutral” from “Buy” on May 09, 2025 while assigning a price target of $23. Cantor Fitzgerald issued its recommendations for the stock as it initiated the price target for the stock is $44.
Over the week, APLS’s stock price is moving 8.68% up while it is 1.66% when we observe its performance for the past one month. Year-to-date it is -44.28% down and over the past year, the stock is showing a downside performance of -58.86%.
Currently, Apellis Pharmaceuticals Inc’s total number of outstanding shares is 125.66M with 13.73% of that held by the insiders while 104.74% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -35.68% and return on equity (ROE) at -103.82%. Stock’s beta reads 0.69. Stock has a price to book (P/B) ratio of 13.61 while price to sale or P/S ratio amounts to 2.88. Its return on asset (ROA) is -27.29% on average.
